Kewalramani Reshma

CEO & President, DirectorVERTEX PHARMACEUTICALS INC / MA (VRTX) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$19.7M
Net Open-Market Flow
-$19.7M
Transactions
13
13 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 27, 2026Sell(S)3K$488.27$1.6M132K
Feb 27, 2026Sell(S)3K$487.13$1.2M135K
Feb 27, 2026Sell(S)240$482.84$116K138K
Feb 27, 2026Sell(S)120$481.50$58K138K
Feb 27, 2026Sell(S)400$479.75$192K138K
Feb 27, 2026Sell(S)460$489.32$225K131K
Feb 27, 2026Sell(S)2K$496.95$857K98K
Feb 27, 2026Sell(S)6K$496.16$3.0M100K
Feb 27, 2026Sell(S)3K$490.54$1.3M129K
Feb 27, 2026Sell(S)949$491.30$466K128K
Feb 27, 2026Sell(S)3K$493.29$1.2M125K
Feb 27, 2026Sell(S)3K$494.33$1.7M122K
Feb 27, 2026Sell(S)16K$495.38$7.7M106K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000875320-26-000129) within minutes of acceptance. Every field above traces to the original document. Verify it directly: